Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer — Stella

Home/Metastatic Breast Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Metastatic Breast Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong

Key details

Phase

Early testing

Sponsor

Sun Yat-sen University

Enrollment target

~20 participants

Started

January 2025

Primary completion

June 2026

Age range

18 Years and older

Sex

Female only

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

Last updated April 2025